Skip to main content
Top
Published in: Strahlentherapie und Onkologie 7/2017

01-07-2017 | Literatur kommentiert

Konsolidierende Lokaltherapie verbessert progressionsfreies Überleben von Patienten mit oligometastasiertem NSCLC

Ergebnisse einer randomisierten Phase-II-Studie

Authors: Dr. med. Tobias Finazzi, Prof. Dr. med. Matthias Guckenberger

Published in: Strahlentherapie und Onkologie | Issue 7/2017

Login to get access

Auszug

Gomez und Mitarbeiter untersuchten in einer prospektiv randomisierten, multizentrischen Phase-II-Studie den Nutzen einer konsolidierenden Lokaltherapie nach Erstlinientherapie bei Patienten mit oligometastasierten, nicht-kleinzelligen Lungenkarzinomen (NSCLC). …
Literature
1.
go back to reference Gomez DR, Blumenschein GR Jr., Lee JJ et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672–1682CrossRefPubMed Gomez DR, Blumenschein GR Jr., Lee JJ et al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: A multicentre, randomised, controlled, phase 2 study. Lancet Oncol 17:1672–1682CrossRefPubMed
2.
go back to reference De Ruysscher D, Wanders R, van Baardwijk A et al (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: Long-term results of a prospective phase II trial (nct01282450). J Thorac Oncol 7:1547–1555CrossRefPubMed De Ruysscher D, Wanders R, van Baardwijk A et al (2012) Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: Long-term results of a prospective phase II trial (nct01282450). J Thorac Oncol 7:1547–1555CrossRefPubMed
3.
go back to reference Downey RJ, Ng KK, Kris MG et al (2002) A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer 38:193–197CrossRefPubMed Downey RJ, Ng KK, Kris MG et al (2002) A phase II trial of chemotherapy and surgery for non-small cell lung cancer patients with a synchronous solitary metastasis. Lung Cancer 38:193–197CrossRefPubMed
4.
go back to reference Iyengar P, Kavanagh BD, Wardak Z et al (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32:3824–3830CrossRefPubMed Iyengar P, Kavanagh BD, Wardak Z et al (2014) Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol 32:3824–3830CrossRefPubMed
5.
go back to reference Rusthoven CG, Yeh N, Gaspar LE (2015) Radiation therapy for oligometastatic non-small cell lung cancer: Theory and practice. Cancer J 21:404–412CrossRefPubMed Rusthoven CG, Yeh N, Gaspar LE (2015) Radiation therapy for oligometastatic non-small cell lung cancer: Theory and practice. Cancer J 21:404–412CrossRefPubMed
6.
go back to reference Lussier YA, Khodarev NN, Regan K et al (2012) Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific micrornas. PLOS ONE 7:e50141CrossRefPubMedPubMedCentral Lussier YA, Khodarev NN, Regan K et al (2012) Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific micrornas. PLOS ONE 7:e50141CrossRefPubMedPubMedCentral
7.
go back to reference Widder J, Klinkenberg TJ, Ubbels JF et al (2013) Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol 107:409–413CrossRefPubMed Widder J, Klinkenberg TJ, Ubbels JF et al (2013) Pulmonary oligometastases: Metastasectomy or stereotactic ablative radiotherapy? Radiother Oncol 107:409–413CrossRefPubMed
8.
go back to reference Ashworth AB, Senan S, Palma DA et al (2014) An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 15:346–355CrossRefPubMed Ashworth AB, Senan S, Palma DA et al (2014) An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 15:346–355CrossRefPubMed
9.
go back to reference Rieber J, Abbassi-Senger N, Adebahr S et al (2016) Influence of institutional experience and technological advances on outcome of stereotactic body radiation therapy for oligometastatic lung disease. Int J Radiat Oncol Biol Phys. doi:10.1016/j.ijrobp.2016.09.026 PubMed Rieber J, Abbassi-Senger N, Adebahr S et al (2016) Influence of institutional experience and technological advances on outcome of stereotactic body radiation therapy for oligometastatic lung disease. Int J Radiat Oncol Biol Phys. doi:10.​1016/​j.​ijrobp.​2016.​09.​026 PubMed
10.
go back to reference Congedo MT, Cesario A, Lococo F et al (2012) Surgery for oligometastatic non-small cell lung cancer: Long-term results from a single center experience. J Thorac Cardiovasc Surg 144:444–452CrossRefPubMed Congedo MT, Cesario A, Lococo F et al (2012) Surgery for oligometastatic non-small cell lung cancer: Long-term results from a single center experience. J Thorac Cardiovasc Surg 144:444–452CrossRefPubMed
11.
go back to reference Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the rtog 9508 randomised trial. Lancet 363:1665–1672CrossRefPubMed Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the rtog 9508 randomised trial. Lancet 363:1665–1672CrossRefPubMed
12.
go back to reference Lewis SL, Porceddu S, Nakamura N et al (2015) Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: An international survey of >1000 radiation oncologists. Am J Clin Oncol. doi:10.1097/coc.0000000000000169 PubMed Lewis SL, Porceddu S, Nakamura N et al (2015) Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: An international survey of >1000 radiation oncologists. Am J Clin Oncol. doi:10.​1097/​coc.​0000000000000169​ PubMed
Metadata
Title
Konsolidierende Lokaltherapie verbessert progressionsfreies Überleben von Patienten mit oligometastasiertem NSCLC
Ergebnisse einer randomisierten Phase-II-Studie
Authors
Dr. med. Tobias Finazzi
Prof. Dr. med. Matthias Guckenberger
Publication date
01-07-2017
Publisher
Springer Berlin Heidelberg
Published in
Strahlentherapie und Onkologie / Issue 7/2017
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-017-1147-4

Other articles of this Issue 7/2017

Strahlentherapie und Onkologie 7/2017 Go to the issue